PERNIX THERAPEUTICS HLDGS IN's ticker is PTX and the CUSIP is 71426V108. A total of 43 filers reported holding PERNIX THERAPEUTICS HLDGS IN in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $24,000 | +20.0% | 38,332 | -14.8% | 0.00% | – |
| Q2 2016 | $20,000 | -86.5% | 44,965 | -68.1% | 0.00% | – |
| Q1 2016 | $148,000 | -71.9% | 141,172 | -20.9% | 0.00% | – |
| Q4 2015 | $526,000 | +6.7% | 178,444 | +14.3% | 0.00% | – |
| Q3 2015 | $493,000 | -47.5% | 156,109 | -1.6% | 0.00% | – |
| Q2 2015 | $939,000 | -61.5% | 158,671 | -30.4% | 0.00% | -100.0% |
| Q1 2015 | $2,438,000 | +17.3% | 228,058 | +3.1% | 0.00% | 0.0% |
| Q4 2014 | $2,078,000 | +75.1% | 221,303 | +43.2% | 0.00% | – |
| Q3 2014 | $1,187,000 | -44.0% | 154,554 | -34.5% | 0.00% | – |
| Q2 2014 | $2,118,000 | +539.9% | 235,846 | +281.3% | 0.00% | – |
| Q1 2014 | $331,000 | +110.8% | 61,859 | -0.5% | 0.00% | – |
| Q4 2013 | $157,000 | -51.5% | 62,168 | -47.9% | 0.00% | – |
| Q3 2013 | $324,000 | +91.7% | 119,278 | +154.5% | 0.00% | – |
| Q2 2013 | $169,000 | – | 46,861 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 4,800,000 | $15,168,000 | 5.18% |
| Avoro Capital Advisors LLC | 6,004,564 | $18,974,000 | 4.93% |
| DG Capital Management, LLC | 695,808 | $2,199,000 | 2.56% |
| ACUTA CAPITAL PARTNERS, LLC | 1,108,719 | $3,504,000 | 2.03% |
| Aisling Capital LLC | 2,010,000 | $6,352,000 | 1.12% |
| Broadfin Capital, LLC | 6,090,829 | $19,247,000 | 1.07% |
| KOPP INVESTMENT ADVISORS LLC | 375,293 | $1,186,000 | 0.64% |
| SEARLE & CO. | 172,500 | $545,000 | 0.56% |
| Elk Creek Partners, LLC | 1,864,515 | $5,892,000 | 0.48% |
| WALL STREET ASSOCIATES | 696,300 | $2,200,000 | 0.42% |